News >

Frontline Daratumumab/VRd Regimen Improves sCR Rate in Transplant-Eligible Myeloma

Gina Columbus @ginacolumbusonc
Published: Monday, Jul 08, 2019

Jan van de Winkel, PhD

Jan van de Winkel, PhD
The quadruplet regimen of daratumumab (Darzalex), lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone elicited a higher stringent complete response (sCR) rate compared with lenalidomide, bortezomib, and dexamethasone (VRd) alone in patients with transplant-eligible, newly diagnosed multiple myeloma, meeting the primary endpoint of the phase II GRIFFIN study.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x